JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

47.79 3.94

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

45.02

Макс.

48.58

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-12M

-33M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+11.09% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

267M

2.9B

Предыдущая цена открытия

43.85

Предыдущая цена закрытия

47.79

Новостные настроения

By Acuity

50%

50%

152 / 352 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 февр. 2026 г., 00:00 UTC

Популярные акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 февр. 2026 г., 22:55 UTC

Отчет

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 февр. 2026 г., 21:44 UTC

Отчет

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 февр. 2026 г., 21:39 UTC

Отчет

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 февр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 февр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 февр. 2026 г., 23:46 UTC

Обсуждения рынка

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 февр. 2026 г., 23:45 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 февр. 2026 г., 23:32 UTC

Обсуждения рынка

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 февр. 2026 г., 22:59 UTC

Приобретения, слияния, поглощения

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 февр. 2026 г., 22:30 UTC

Отчет

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 февр. 2026 г., 22:30 UTC

Отчет

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 февр. 2026 г., 22:21 UTC

Отчет

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 февр. 2026 г., 22:17 UTC

Обсуждения рынка

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 февр. 2026 г., 22:15 UTC

Обсуждения рынка

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 февр. 2026 г., 22:00 UTC

Обсуждения рынка

ESG Roundup: Market Talk

4 февр. 2026 г., 21:53 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 февр. 2026 г., 21:51 UTC

Отчет

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Financial Services Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Auto & Transport Roundup: Market Talk

4 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

4 февр. 2026 г., 21:45 UTC

Отчет

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 февр. 2026 г., 21:44 UTC

Отчет

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 февр. 2026 г., 21:43 UTC

Отчет

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 февр. 2026 г., 21:41 UTC

Отчет

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 февр. 2026 г., 21:36 UTC

Обсуждения рынка

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 февр. 2026 г., 21:30 UTC

Отчет

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 февр. 2026 г., 21:30 UTC

Отчет

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 февр. 2026 г., 21:30 UTC

Отчет

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

11.09% рост

Прогноз на 12 месяцев

Средняя 52 USD  11.09%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

152 / 352Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat